Identification of New N-methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors
Pharmaceuticals · 06.01.2023 · 16 (1) · 83
DOI: 10.3390/ph16010083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 06.01.2023. Verfasst von Ashraf K El-Damasy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Science & Technology (NST) grant, National Research Foundation of Korea (NRF), Korea Research Fellowship Program grant.
Abstract (Originalsprache)
Monoamine oxidase-B (MAO-B), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE) have been considered target enzymes of depression and neurodegenerative diseases, including Alzheimer’s disease (AD). In this study, seventeen N-methyl-piperazine chalcones were synthesized, and their inhibitory activities were evaluated against the target enzymes. Compound 2k (3-trifluoromethyl-4-fluorinated derivative) showed the highest selective inhibition against MAO-B with an IC50 of 0.71 μM and selectivity index (SI) of 56.34, followed by 2n (2-fluoro-5-bromophenyl derivative) (IC50 = 1.11 μM, SI = 16.04). Compounds 2k and 2n were reversible competitive MAO-B inhibitors with Ki values of 0.21 and 0.28 μM, respectively. Moreover, 2k and 2n effectively inhibited AChE with IC50 of 8.10 and 4.32 μM, which underscored their multi-target inhibitory modes. Interestingly, compound 2o elicited remarkable inhibitions over MAO-B, AChE, and BChE with IC50 of 1.19–3.87 μM. A cell-based assay of compounds 2k and 2n against Vero normal cells pointed out their low cytotoxicity. In a docking simulation, 2k showed the lowest energy for MAO-B (−11.6 kcal/mol) with four hydrogen bonds and two π-π interactions. Furthermore, in silico studies were conducted, and disclosed that 2k and 2n are expected to possess favorable pharmacokinetic properties, such as the ability to penetrate the blood–brain barrier (BBB). In view of these findings, compounds 2k and 2n could serve as promising potential candidates for the treatment of neurodegenerative diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
- Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea.
- Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.
- Department of Bioinformatics, KRIBB School of Bioscience, University of Science and Technology (UST), Daejeon 34113, Republic of Korea.
ORCID-Profile: Hoon Kim, Gyochang Keum
Förderung
- National Research Council of Science & Technology (NST) grant
- National Research Foundation of Korea (NRF)
- Korea Research Fellowship Program grant
- Institutional Program grant by the Korea Institute of Science and Technology
- Korean Government (MSIT)
- Ministry of Science and ICT
- Korea Institute of Science and Technology
Zitieren
APA
El-Damasy, A. K., Park, J. E., Kim, H. J., Lee, J., Bang, E. K., Kim, H., & Keum, G. (2023). Identification of New N-methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors. Pharmaceuticals, 16(1), 83. https://doi.org/10.3390/ph16010083
Vancouver
El-Damasy AK, Park JE, Kim HJ, Lee J, Bang EK, Kim H, et al. Identification of New N-methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors. Pharmaceuticals. 2023;16(1):83. doi:10.3390/ph16010083
BibTeX
@article{ElDamasy2023,
author = {El-Damasy, Ashraf K and Park, Jong Eun and Kim, Hyun Ji and Lee, Jinhyuk and Bang, Eun-Kyoung and Kim, Hoon and Keum, Gyochang},
title = {Identification of New N-methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {1},
pages = {83},
doi = {10.3390/ph16010083}
}
EUVIMED